ChiCTR2100050918 版本V1.1 版本创建时间2022/03/29 19:26:02 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100050918 

最近更新日期:

Date of Last Refreshed on:

2021-09-08 16:12:13 

注册时间:

Date of Registration:

2021-09-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请与我们联系上传伦理审批文件。 OCTA在视盘新生血管疾病中应用和探索

Public title:

Application and exploration of OCTA in optic disc neovascular disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

OCTA在视盘新生血管疾病中应用和探索

Scientific title:

Application and exploration of OCTA in optic disc neovascular disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王相宁 

研究负责人:

王相宁 

Applicant:

wang xiangning 

Study leader:

wang xiangning 

申请注册联系人电话:

Applicant telephone:

18930170516

研究负责人电话:

Study leader's
telephone:

18930170516

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xnwang21@163.com

研究负责人电子邮件:

Study leader's E-mail:

xnwang21@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区宜山路600号

研究负责人通讯地址:

上海市徐汇区宜山路600号

Applicant address:

600 Yishan Road, Xuhui District, Shanghai, China

Study leader's address:

600 Yishan Road, Xuhui District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

200323

研究负责人邮政编码:

Study leader's postcode:

200323

申请人所在单位:

上海市第六人民医院

Applicant's institution:

Shanghai Sixth People's Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第六人民医院

Primary sponsor:

Shanghai Sixth People's Hospital

研究实施负责(组长)单位地址:

上海市徐汇区宜山路600号

Primary sponsor's address:

600 Yishan Road, Xuhui District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第六人民医院

具体地址:

徐汇区宜山路600号

Institution
hospital:

Shanghai Sixth People's Hospital

Address:

600 Yishan Road, Xuhui District

经费或物资来源:

上海市第六人民医院院级课题

Source(s) of funding:

shanghai Sixth People's Hospital

研究疾病:

视盘新生血管  

Target disease:

optic disc neovascular disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

通过无创的OCTA检测技术,分析视盘新生血管的影像学结构特征,并随访观察其治疗后的变化情况  

Objectives of Study:

Analyze the imaging structural characteristics of optic disc neovascularization through non-invasive OCTA detection technology, and follow-up to observe the changes after treatment

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①年龄>18岁 糖尿病患者
②无影响眼底检查的屈光介质混浊及瞳孔缩小
③根据眼底照相或OCT或FA临床诊断为视盘新生血管

Inclusion criteria

①Age>18 years old diabetic patients
②There is no opacity of refractive medium and pupil reduction that affect fundus examination
③ Clinical diagnosis of optic disc neovascularization based on fundus photography or OCT or FA

排除标准:

1)任一眼有活动性眼部感染(如眼睑炎、角膜炎、巩膜炎、结膜炎等);
2)目标眼除糖尿病外,还患有其他眼科情况(如视网膜静脉阻塞(RVO)、CNV、视网膜脱落、黄斑裂孔、黄斑区视网膜牵拉、视网膜前膜等);
3)研究者认为目标眼白内障可能影响检查或试验结果判断,或未来6个月内需手术治疗;

Exclusion criteria:

1) Any eye has active eye infection (such as blepharitis, keratitis, scleritis, conjunctivitis, etc.);
2) In addition to diabetes, the target eye also suffers from other ophthalmological conditions (such as retinal vein occlusion (RVO), CNV, retinal detachment, macular hole, retinal traction in the macular area, epiretinal membrane, etc.);
3) The investigator believes that the target eye cataract may affect the judgment of the examination or test results, or surgery is required in the next 6 months;

研究实施时间:

Study execute time:

From 2021-10-11 00:00:00 To 2023-10-11 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-10-11 00:00:00 To 2023-10-11 00:00:00

干预措施:

Interventions:

组别:

连续入组

样本量:

300

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第六人民医院 

单位级别:

三甲 

Institution
hospital:

Shanghai Sixth People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

新生血管面积

指标类型:

主要指标

Outcome:

New blood vessel area

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Null

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

不需要

Randomization Procedure (please state who generates the random number sequence and by what method):

no need

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data will be disclosed in

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本课题设计有专用数据采集表,专人进行纸质记录和电子图像保存,Access数据库录入,保存于研究者处。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Each patient are required to fill one data table, all the tables and images,Access data base saved by researchers.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-09-08 16:12:09